Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EBT Margin for 6 consecutive years, with 10239.16% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin fell 602569.0% year-over-year to 10239.16%, compared with a TTM value of 12034.97% through Sep 2025, up 346609.0%, and an annual FY2024 reading of 409.03%, up 913237.0% over the prior year.
  • EBT Margin was 10239.16% for Q3 2025 at Barinthus Biotherapeutics, up from 2115100.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 1668600.0% in Q4 2021 and bottomed at 2115100.0% in Q2 2025.
  • Average EBT Margin over 5 years is 18945.75%, with a median of 5220.66% recorded in 2024.
  • The sharpest move saw EBT Margin tumbled -166895902bps in 2022, then skyrocketed 25907331bps in 2023.
  • Year by year, EBT Margin stood at 1668600.0% in 2021, then plummeted by -100bps to 359.02% in 2022, then skyrocketed by 72161bps to 258714.29% in 2023, then plummeted by -105bps to 11969.77% in 2024, then rose by 14bps to 10239.16% in 2025.
  • Business Quant data shows EBT Margin for BRNS at 10239.16% in Q3 2025, 2115100.0% in Q2 2025, and 6227.85% in Q1 2025.